Accessing GLP-1 Medications: What You Need to Know

Navigate branded versus compounded options, understand FDA shortage status, and evaluate telehealth providers offering semaglutide and tirzepatide in 2026.

The GLP-1 Landscape in 2026

GLP-1 receptor agonists have become the most transformative weight loss medications in decades. The excitement is justified—the clinical data is genuinely impressive. But the landscape they inhabit is complicated, rapidly evolving, and full of access friction. Understanding what’s actually available right now requires cutting through both hype and confusion.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) is a hormone your intestines naturally produce when you eat. It signals your pancreas to release insulin, slows gastric emptying, and most relevantly for weight loss—it reduces appetite through the hypothalamus. GLP-1 receptor agonists mimic this hormone, amplifying the appetite-suppression signal while improving glucose control. (For deeper biochemistry, see our semaglutide and tirzepatide articles.)

The three FDA-approved GLP-1 medications currently available are:

• Semaglutide (Ozempic for diabetes, Wegovy for weight loss)—approved by FDA in 2017 for diabetes, 2021 for weight loss. Manufactured by Novo Nordisk.
• Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss)—approved by FDA in 2022 for diabetes, 2023 for weight loss. Manufactured by Eli Lilly. A dual GLP-1/GIP receptor agonist, not just GLP-1.
• Liraglutide (Saxenda for weight loss, Victoza for diabetes)—older GLP-1 agonist approved in 2014. Less commonly used now because newer options have better data.

In development: Retatrutide, a triple agonist hitting GLP-1, GIP, and glucagon receptors simultaneously, is in Phase III trials. The early data suggests weight loss exceeding even tirzepatide. It is not yet FDA approved.

The Weight Loss Data

The clinical evidence is substantial. In the STEP trials (semaglutide), participants lost an average of 15–18% of body weight over 68 weeks. In the SURMOUNT trials (tirzepatide), the weight loss reached 20–22% across different dose levels, with the highest dose producing losses approaching 25%. For context: lifestyle interventions alone typically achieve 5–10% weight loss. These medications are in a different category.

That data is why access matters so much. People have legitimate reasons to pursue these medications, and they have legitimate reasons to be frustrated by cost and availability barriers.

Branded vs. Compounded: Understanding the Distinction

This is the central question most people face when looking for access to GLP-1 medications. The difference is not small, and it is not purely a matter of cost—it affects everything from efficacy predictability to legal status to your recourse if something goes wrong.

Branded GLP-1 Medications

What they are: Semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) manufactured at pharmaceutical scale in FDA-regulated facilities. The drug substance is synthesized in the same way every time. The fill-finish process (putting the drug into pens or vials) is identical every time. Quality control is constant. The molecule you inject on day one is the same molecule you inject six months later.

FDA approval status: Approved through the New Drug Application (NDA) process, which means the manufacturer has submitted clinical trial data demonstrating safety and efficacy. The FDA has reviewed manufacturing standards, stability data, and long-term safety in thousands of people.

Supply status in early 2026: After widespread shortages in 2023–2024, branded GLP-1 medications are returning to more reliable availability. Novo Nordisk and Eli Lilly have significantly expanded manufacturing capacity. However, shortages can still occur based on demand and manufacturing disruptions. Check current availability with your pharmacy.

Compounded GLP-1 Medications

What they are: Compounded semaglutide and tirzepatide are made by compounding pharmacies—smaller facilities that mix, measure, and package medications according to individual prescriptions or for limited production runs. These are not manufactured at the scale of branded pharmaceuticals and are not subject to the same FDA approval process.

The legal framework: Under Section 503A of the FDA Modernization Act (FDAMA), compounding pharmacies can legally prepare compounded versions of FDA-approved drugs if those drugs are in short supply. The FDA has declared semaglutide in shortage, which allows compounders to legally produce it. Tirzepatide’s shortage declaration has been more variable and depends on checking the FDA’s current shortage list.

When a drug is no longer in shortage, the FDA has the authority to issue cease-and-desist letters to compounders. This happened to some semaglutide compounders in 2024 when shortages temporarily eased. The landscape remains uncertain: as branded supply stabilizes, the legal window for compounding may narrow further.

The Formulation Debate: Semaglutide Base vs. Semaglutide Sodium

This is where things get legally murky. Novo Nordisk manufactures semaglutide as the freebase (base form). Some compounding pharmacies have argued that by producing semaglutide as a sodium salt (a different chemical form), they are creating a legally distinct product—and therefore not infringing on Novo Nordisk’s patent or shortage declaration.

The pharmacology is similar but not identical. Semaglutide sodium has different solubility properties and may have different stability profiles than the freebase. Whether this meaningfully affects clinical outcomes in humans is not well established, because there are no head-to-head trials comparing them.

The legal question remains unsettled. Courts may ultimately determine that semaglutide sodium is too close to semaglutide base to be a distinct product. Or the FDA’s stance may shift. This is not settled science or law—it is an active legal gray zone.

Quality Variance in Compounded Products

The most important caveat: not all compounding pharmacies are equivalent. A compounded medication is only as good as the pharmacy producing it. Unlike branded manufacturers, which face standardized FDA oversight, compounders operate under a wider range of quality standards. Some compounders maintain rigorous standards and obtain Certificates of Analysis (CoA) from third-party labs. Others do not.

When evaluating a compounded GLP-1 medication, you should require:

• PCAB (Pharmacy Compounding Accreditation Board) accreditation for the compounding pharmacy
• Certificate of Analysis from a third-party lab showing purity (≥98%), potency, sterility, endotoxin testing, and water content
• Stability testing data showing the product remains potent under your storage conditions
• Transparency about the specific formulation (base vs. salt, excipients, concentration)

If a provider or pharmacy cannot or will not provide a CoA, that is a major red flag. See our guide on reading Certificates of Analysis for what to look for.

The Cost Reality

Branded Medication Costs

List price: Semaglutide (Wegovy) carries a list price of approximately $1,300/month. Tirzepatide (Zepbound) is similar at roughly $1,100–1,300/month. These are manufacturer’s suggested retail prices. Few people pay these prices directly.

With insurance: Coverage varies widely depending on your insurance plan and the indication. Ozempic (diabetes indication) is more likely to be covered than Wegovy (weight loss indication). Some plans require prior authorization, step therapy (trying cheaper alternatives first), or high deductibles. Copays range from $0 to $400+ per month depending on your plan tier.

Manufacturer assistance programs: Novo Nordisk’s Novo Care and Eli Lilly’s Lilly Cares offer copay cards that cap your out-of-pocket costs at $50/month for eligible patients. If you have insurance, these can dramatically reduce your cost. Uninsured patients may qualify for free or reduced-cost medication through income-based assistance programs.

HSA/FSA eligibility: Both semaglutide and tirzepatide are eligible for Health Savings Accounts and Flexible Spending Accounts. If you have one of these accounts, you can use pre-tax dollars, effectively reducing your cost by 25–35% depending on your tax bracket.

Compounded Medication Costs

Compounded semaglutide typically costs $150–400/month depending on the compounding pharmacy, dose, and formulation. Compounded tirzepatide costs similarly. This is roughly one-third to one-quarter of the branded list price.

However, compounded medications are rarely covered by insurance. You are paying out of pocket. Some telehealth platforms that prescribe compounded GLP-1s have subscription models ($100–300/month for the prescription and initial evaluation, plus pharmacy costs). Others charge per-prescription fees.

The Cost-Quality Tradeoff

Cheaper is not automatically worse, but it demands more diligence on your part. A $200/month compounded product from a PCAB-accredited pharmacy with full third-party lab verification is genuinely safer than a $1,300 branded product without medical oversight. But a $200 compounded product with no CoA, no quality testing, and no medical evaluation is a lottery ticket.

The deciding factor is not price—it is whether you have reliable assurance that what you are receiving is what you think you are receiving. For branded medications, the FDA’s oversight provides that assurance. For compounded medications, you have to verify it yourself by demanding a CoA and proof of accreditation.

How to Access Branded GLP-1 Medications

Through Your Primary Care Physician or Endocrinologist

This is the most straightforward path if you have an established relationship with a primary care doctor or endocrinologist. Your doctor can evaluate whether a GLP-1 medication is appropriate for you, order the necessary baseline labs, write a prescription, and monitor your response and side effects over time.

The friction: Some primary care physicians are uncomfortable prescribing GLP-1s for weight loss (as opposed to diabetes), either because they lack training or because they believe weight loss medications should be managed by specialists. If you encounter resistance, ask for a referral to an obesity medicine specialist or an endocrinologist.

Through Telehealth Platforms Specializing in Weight Management

Multiple telehealth platforms now focus specifically on GLP-1 prescribing: Calibrate, Found, Ro, Noom, Spruce, and others. These platforms typically offer:

• Online consultation with a provider (usually a nurse practitioner or physician assistant trained in weight management)
• Basic medical evaluation to confirm eligibility
• Prescription and coordination with a pharmacy (usually branded)
• Ongoing check-ins and dose adjustments
• Additional services (some offer concurrent behavioral coaching or nutritional support)

Quality and thoroughness vary significantly. See our guide on evaluating telehealth providers for what to look for.

Insurance Prior Authorization

Most insurance plans require prior authorization before covering a GLP-1 medication. The insurer wants to verify that you meet their eligibility criteria before approving the claim.

Typical requirements:

• BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity (diabetes, hypertension, sleep apnea, etc.)
• Documentation of previous weight loss attempts
• For some plans: evidence that you have tried and failed cheaper weight loss medications (step therapy)
• Provider documentation supporting medical necessity

The step therapy problem: Some plans require you to try and fail other weight loss medications (phentermine, naltrexone-bupropion, orlistat) before approving a GLP-1. This delays access and, frankly, makes little sense given the superior efficacy of GLP-1s. If you encounter this, ask your provider to appeal the requirement by documenting medical reasons why alternatives are contraindicated for you.

If authorization is denied: You have the right to appeal. Your provider can submit additional medical documentation supporting the prescription. Many insurers approve on second review.

Manufacturer Patient Assistance Programs

If you are uninsured or underinsured, both Novo Nordisk and Eli Lilly offer programs:

• Novo Care (Novo Nordisk): Copay cards capping out-of-pocket at $50/month for insured patients. Uninsured patients with income below 400% of federal poverty level may qualify for free medication.
• Lilly Cares (Eli Lilly): Similar copay support and uninsured patient programs.

Contact these programs directly or ask your provider’s office to help you apply. The process typically takes 2–4 weeks.

How to Access Compounded GLP-1 Medications

Telehealth Platforms Prescribing Compounded Versions

A growing ecosystem of telehealth platforms specializes in prescribing compounded semaglutide and tirzepatide. Some focus exclusively on GLP-1s; others offer them as part of a broader peptide practice. These platforms typically charge a monthly subscription ($100–300) plus pharmacy costs ($150–400).

The clinical model is usually lighter-touch: a quick initial evaluation to confirm you don’t have contraindications (personal history of medullary thyroid cancer, for instance), a prescription, and minimal follow-up. Many do not require baseline labs. Some do not coordinate with your primary care physician.

Be cautious. The most legitimate compounded GLP-1 providers will:

• Require a medical evaluation (even if brief) before prescribing
• Obtain baseline labs (at minimum: fasting glucose, HbA1c, kidney function)
• Disclose which compounding pharmacy they use
• Provide you with a full Certificate of Analysis for your medication
• Offer ongoing monitoring and dose adjustments
• Be transparent about the limitations of compounded products and the uncertain legal status

If a platform guarantees prescriptions without evaluation, offers to prescribe compounded GLP-1s to anyone without baseline labs, or cannot or will not provide a CoA, it is a problematic provider. Avoid it.

Evaluating Compounding Pharmacies

PCAB accreditation: The Pharmacy Compounding Accreditation Board (PCAB) maintains standards for compounding pharmacies. PCAB-accredited pharmacies undergo external audits, maintain detailed quality assurance protocols, and are held to higher standards than non-accredited compounders. Check PCAB’s directory to verify accreditation.

Sterile compounding standards: For injectable GLP-1 medications, the compounding must occur in a USP <797>-compliant environment (USP Chapter 797 defines standards for sterile compounding). Ask your pharmacy whether they operate under USP <797> standards. If they don’t know what you’re asking, that’s a problem.

Certificate of Analysis requirements: A legitimate CoA should include:

• Purity testing (HPLC): ≥98% purity is the standard
• Potency confirmation: the actual concentration matches the labeled concentration
• Sterility testing: verification that the product is free from bacterial and fungal contamination
• Endotoxin testing: gram-negative bacteria produce endotoxins that can cause severe immune reactions
• Water content: for injectable products, excess water can affect stability and potency
• pH testing: incorrect pH can affect sterility and stability

The lab doing the analysis should be an independent, third-party lab—not the compounding pharmacy itself. Pharmacy in-house testing is better than nothing, but independent verification is more trustworthy.

Subcutaneous vs. Sublingual vs. Oral Formulations

Compounding pharmacies have experimented with different routes of administration beyond the standard subcutaneous injection. Some offer sublingual (under-the-tongue) or oral formulations.

The evidence: Branded semaglutide and tirzepatide are both designed as subcutaneous injections. Oral semaglutide (Rybelsus) exists but has much lower bioavailability and requires a different (higher) dose. There is no human evidence supporting the efficacy of sublingual semaglutide or tirzepatide. These formulations are theoretical, not evidence-based.

If you encounter compounded sublingual or oral GLP-1 products, understand that you are essentially experimenting. The absorption kinetics, actual bioavailability, and clinical effectiveness are unknown. The CoA might confirm the product contains the labeled dose of the drug, but whether you actually absorb and utilize that dose is a separate question.

Stick with subcutaneous injection if you want predictable results backed by human evidence.

Red Flags in Compounded GLP-1 Providers

Avoid providers that:

• Claim to “guarantee” prescriptions or offer prescriptions without medical evaluation
• Cannot or will not provide a Certificate of Analysis
• Do not require baseline labs or ongoing monitoring
• Promote heavily on social media with influencer testimonials rather than medical education
• Will not disclose which pharmacy they use or claim all pharmacies are “the same”
• Refuse to discuss potential side effects or drug interactions
• Offer extreme discount pricing inconsistent with the cost of quality compounding

The compounded GLP-1 space includes both legitimate, rigorous providers and opportunistic ones. Diligence on your part—asking hard questions about quality assurance, demanding documentation, verifying accreditation—is essential.

The Medical Evaluation for GLP-1 Medications

GLP-1 receptor agonists are powerful medications. They require more medical oversight than many weight loss medications, not because they are dangerously toxic, but because they alter multiple systems—glucose homeostasis, gastric motility, appetite regulation, thyroid signaling—and individual variation matters.

Contraindications

Some people should not take GLP-1 medications:

• Personal history of medullary thyroid carcinoma (MTC): GLP-1 receptor activation increases calcitonin secretion, which is the tumor marker for MTC. If you have a history of MTC, GLP-1 medications are contraindicated.
• Family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2): Even without personal disease, genetic predisposition to MTC makes GLP-1 medications risky. Screening for RET mutations is recommended before starting.
• Pregnancy or planning pregnancy: GLP-1 medications have not been studied in pregnancy. Current guidance is to discontinue them if you become pregnant, which means they are not suitable for contraception-free sexual activity.

Breastfeeding is generally considered compatible with GLP-1 medications, but the data is limited. Discuss this with your provider if applicable.

Drug Interactions

GLP-1 medications interact with several drug classes:

• Insulin: GLP-1 medications increase insulin sensitivity and lower blood glucose. If you are taking insulin, your dose may need to be reduced to avoid hypoglycemia. This is a significant interaction—not a contraindication, but requiring monitoring and adjustment.
• Sulfonylureas (glyburide, glipizide, glimepiride): Similar to insulin—increased risk of hypoglycemia. Dose reduction may be necessary.
• Oral medications requiring rapid absorption: GLP-1 medications slow gastric emptying, which means oral medications take longer to be absorbed. This is most relevant for oral contraceptives—the FDA label recommends using a backup contraceptive method for the first month of GLP-1 therapy. For other oral medications (antibiotics, etc.), spacing doses away from GLP-1 injections may help.

Baseline Labs

Before starting a GLP-1 medication, you should have baseline lab work to establish your starting point and screen for contraindications:

• Fasting glucose and HbA1c: To assess baseline glucose control and establish whether diabetes is present.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides): To establish baseline cardiovascular risk. GLP-1 medications improve lipid profiles in most people.
• Kidney function (creatinine, eGFR): GLP-1 medications are renally cleared. Severe kidney disease may affect dosing. More importantly, establishing baseline kidney function helps monitor for rare GLP-1–associated kidney complications.
• Liver enzymes (ALT, AST): Baseline hepatic function should be documented.
• Thyroid panel (TSH, free T4): To establish baseline thyroid function and screen for preexisting thyroid disease. GLP-1 medications do not cause thyroiditis, but baseline assessment is still wise.
• Calcitonin (optional but prudent): If you have family history of MTC or MEN2, baseline calcitonin helps establish normal range and can catch early elevation.

Dose Titration

Both semaglutide and tirzepatide use a slow titration schedule. This is not arbitrary—starting with a low dose minimizes GI side effects and allows your body to adjust to the medication.

Semaglutide titration (Wegovy): Weeks 1–4: 0.25 mg weekly → Weeks 5–8: 0.5 mg weekly → Weeks 9–12: 1 mg weekly → Weeks 13–16: 1.7 mg weekly → Week 17+: 2.4 mg weekly (maintenance). If you experience severe nausea, you can stay at a lower dose.

Tirzepatide titration (Zepbound): Weeks 1–4: 2.5 mg weekly → Weeks 5–8: 5 mg weekly → Weeks 9–12: 7.5 mg weekly → Weeks 13–16: 10 mg weekly → Weeks 17–20: 12.5 mg weekly → Week 21+: 15 mg weekly (maintenance). Like semaglutide, you can stay at lower doses if side effects are limiting.

Do not skip ahead in the titration. This is where many unsuccessful outcomes originate—people jump to higher doses faster than the protocol recommends because they are impatient, then experience severe nausea and give up. Follow the schedule.

Side Effects and What to Expect

Gastrointestinal side effects (expected): The most common adverse effects are nausea, vomiting, constipation, and diarrhea. These are direct pharmacological effects of GLP-1 agonism—delayed gastric emptying and altered gut motility. They are usually mild to moderate and dose-dependent. Most people adapt within 2–4 weeks at each dose level.

Management: eat smaller meals, avoid fatty foods, stay hydrated, and be patient. Anti-nausea medications (metoclopramide, ondansetron) can help temporarily. Most side effects resolve as your body adjusts.

Serious but rare side effects: The FDA black box warning for GLP-1 medications flags pancreatitis and thyroid cancer risk. Pancreatitis is rare (~0.1% incidence in trials) but serious. Symptoms include severe abdominal pain, especially in the upper abdomen, sometimes with vomiting. Stop the medication and seek emergency care if this occurs.

Thyroid cancer risk: The animal toxicology data (rodent studies) showed increased medullary thyroid cancer at high doses. This has not been observed in human trials, but the FDA requires warnings and monitoring. If you develop thyroid nodules or have family history of MTC, discuss with your provider.

Gallbladder issues: Rapid weight loss can precipitate gallstone formation. This is a general risk with any rapid weight loss, not specific to GLP-1s, but it is more common than with weight loss from diet alone. Symptoms include upper right abdominal pain. If you develop this, imaging (ultrasound) will confirm.

Overall, the side effect profile is manageable. Most people tolerate GLP-1 medications well once titrated appropriately. But expecting zero side effects is unrealistic.

Semaglutide-Specific Considerations

Semaglutide was the first GLP-1 agonist approved for weight loss and remains the most widely recognized. Understanding its specific pharmacology and available formulations helps with decision-making.

Mechanism and Pharmacology

Semaglutide is a GLP-1 receptor agonist only—it binds to GLP-1 receptors. It does not bind GIP (glucose-dependent insulinotropic peptide) receptors or other appetite-related receptors. This single-mechanism approach contrasts with tirzepatide, which is dual GLP-1/GIP.

Half-life: approximately 7 days. This means you inject once weekly, and the medication circulates in your body for roughly one week before being cleared. The 7-day half-life also means steady-state is reached after about 4 weeks (5 half-lives) of dosing.

Peak plasma concentration occurs 1–3 days after injection. The clinical effect (appetite suppression) builds gradually over the first 2–4 weeks at each dose level.

Ozempic vs. Wegovy: What’s the Difference?

Ozempic and Wegovy are both semaglutide. The difference is indication and dosing:

• Ozempic: Approved for type 2 diabetes. Standard titration caps at 1 mg weekly.
• Wegovy: Approved for chronic weight management. Titration continues to 2.4 mg weekly.

The active pharmaceutical ingredient is identical. Wegovy simply uses higher doses. If your doctor prescribes Ozempic at 1 mg weekly for weight loss, you are on a lower-dose GLP-1 regimen than Wegovy’s maximum, but the medication is the same.

Some insurance plans cover Ozempic (diabetes indication) more readily than Wegovy (weight loss). This has led to off-label use—using Ozempic prescriptions at higher doses for weight loss. This is legal and increasingly common, though prescribing information technically specifies Wegovy for weight loss.

Oral Semaglutide (Rybelsus)

An oral formulation of semaglutide exists: Rybelsus. It uses a delivery technology (SNAC) that allows oral absorption. However, bioavailability is much lower than injectable semaglutide—only about 1% of the oral dose is absorbed. To achieve comparable systemic exposure, oral Rybelsus requires much higher doses (7–14 mg daily) than injectable semaglutide (0.25–2.4 mg weekly).

For weight loss, Rybelsus is less commonly used than injectable Wegovy, partly because the higher daily dosing is inconvenient and partly because efficacy data for weight loss specifically is less robust than for the injection.

Rybelsus requires fasting absorption (no food for 30 minutes before and 2 hours after), which adds logistical burden.

Compounded Semaglutide: What to Verify

If you choose compounded semaglutide, you should specifically verify:

• Chemical form: Is it semaglutide base (freebase) or a salt form (sodium, acetate, etc.)? Ask explicitly. Both exist; the pharmacology is similar but not identical.
• Concentration confirmation: The CoA should verify the actual concentration matches the labeled concentration (e.g., if labeled 5 mg/mL, actual concentration should be 4.9–5.1 mg/mL, not 3 mg/mL).
• Purity ≥98%: HPLC analysis should show purity of at least 98%. Lower purity means contaminants.
• Sterility and endotoxin testing: Essential for injectable products.
• Stability data: The pharmacy should have data confirming the product remains stable at your storage conditions (usually 2–8°C for most compounded semaglutide).

If a compounded semaglutide provider cannot provide these details, that is a serious red flag. You are injecting this substance into your body; verification matters.

Tirzepatide-Specific Considerations

Tirzepatide is newer than semaglutide and represents a different pharmacological approach. The clinical data suggests superior weight loss compared to semaglutide, which has driven rapid adoption and significant compounding interest.

Dual Mechanism: GLP-1/GIP Receptor Agonism

Tirzepatide is a dual GLP-1 receptor agonist AND GIP (glucose-dependent insulinotropic peptide) receptor agonist. This dual mechanism is pharmacologically significant.

GLP-1 receptors mediate appetite suppression and improved insulin secretion. GIP receptors, when activated, amplify insulin secretion further and may contribute to additional appetite suppression through a different pathway. The combination produces synergistic effects—greater weight loss and glucose lowering than either mechanism alone.

Practically, this explains why tirzepatide achieves slightly better weight loss (~22% in SURMOUNT trials) compared to semaglutide (~18% in STEP trials) in head-to-head comparisons.

Dose Titration and Half-Life

Tirzepatide has a shorter half-life (~5 days) compared to semaglutide (~7 days). Still weekly dosing, but tirzepatide clears faster, which may mean slightly more fluctuation in blood levels.

The titration schedule is longer: starting at 2.5 mg, titrating up by 2.5 mg every 4 weeks, reaching a maintenance dose of 10–15 mg. This means a full titration course takes 20–24 weeks compared to semaglutide’s 16–20 weeks. The longer titration can be an advantage (fewer GI side effects) or a disadvantage (longer time to reach full therapeutic dose).

Mounjaro vs. Zepbound

Like semaglutide, tirzepatide has two brand names:

• Mounjaro: Approved for type 2 diabetes (2022). Dosing up to 15 mg weekly.
• Zepbound: Approved for chronic weight management (2023). Same dosing, approved specifically for weight loss.

Again, the medication is identical. The indication determines the brand name and insurance coverage. Some plans cover Mounjaro for diabetes more readily than Zepbound for weight loss.

SURMOUNT-5: Tirzepatide Head-to-Head with Semaglutide

The SURMOUNT-5 trial directly compared tirzepatide to semaglutide. Both groups received active medications at their respective maximum doses. Results: tirzepatide 15 mg weekly achieved approximately 22% weight loss; semaglutide 2.4 mg weekly achieved approximately 16% weight loss. Tirzepatide was superior, though both were effective.

This head-to-head comparison is important context. If you are choosing between the two, tirzepatide’s superior weight loss comes with a longer titration schedule and a more complex mechanism (which means more potential drug interactions, though this is not common).

Compounded Tirzepatide: What to Verify

Compounded tirzepatide is increasingly available. Verification should be similarly rigorous as with compounded semaglutide:

• Concentration verification: CoA confirming actual concentration matches labeled (e.g., if labeled 10 mg/mL, should be 9.8–10.2 mg/mL).
• Purity ≥98%: HPLC should confirm.
• Sterility and endotoxin testing.
• Stability data confirming potency under your storage conditions.

Tirzepatide’s availability in the compounded market is still emerging. The legal status is less settled than semaglutide (which has been explicitly declared in shortage by the FDA). Compounded tirzepatide providers should be transparent about the FDA’s current shortage determination.

As of early 2026, tirzepatide’s FDA shortage status is variable. Always check the current FDA shortage list before committing to a compounded tirzepatide provider.

What Happens When You Stop

This section is crucial and often glossed over. The honest answer is: most people regain weight when they stop GLP-1 medications. Understanding why and what this means for your long-term strategy is essential.

Weight Regain After Discontinuation

The clinical data is unambiguous: when people stop GLP-1 medications, weight returns. In STEP trials, participants who discontinued semaglutide regained approximately 50% of their weight loss over the following year. Similar patterns occur with tirzepatide discontinuation.

This is not a failure of the medication or of the person. It reflects a fundamental biological reality: obesity is not primarily a failure of willpower or adherence to diet. It is a dysregulation of appetite and energy homeostasis driven by multiple biological systems. GLP-1 agonists work by correcting that dysregulation temporarily. When you stop, the dysregulation returns.

The Long-Term Reality: GLP-1 Medications May Be Chronic Therapy

The data suggests that for sustainable weight loss, GLP-1 medications need to be continued long-term. This is the same as any chronic condition medication: you don’t take antihypertensives for 6 months and expect blood pressure to remain controlled after stopping. You take them ongoing.

The practical implications are substantial:

• Cost: long-term therapy means ongoing medication expenses, either through insurance or out of pocket.
• Side effects: you need to manage nausea, GI effects, and other side effects indefinitely, not just during a limited course.
• Monitoring: ongoing medical oversight is necessary to track efficacy, screen for rare complications, and adjust doses as needed.
• Access: the medication needs to remain available and affordable for as long as you want to continue it.

Maintenance Strategies

If you do decide to discontinue or take a break from GLP-1 therapy, some strategies may help minimize regain:

• Dose reduction before discontinuation: Tapering to a lower maintenance dose (e.g., 0.5 mg weekly semaglutide or 2.5 mg weekly tirzepatide) rather than abrupt discontinuation may slow regain. There is limited data on this, but physiologically it makes sense.
• Lifestyle consolidation during treatment: Use the period on medication to establish durable changes—exercise habits, dietary patterns, stress management. These changes may slow regain, though they usually cannot prevent it entirely.
• Combination therapy: Adding other medications (e.g., phentermine, naltrexone-bupropion, topiramate) during or after GLP-1 discontinuation may provide some weight loss support, though the evidence is weaker than for GLP-1 alone.

GLP-1 + GH Secretagogue Interaction: The Glucose Conflict

This is Peptidings-specific content that bears directly on the discontinuation question. Many people use GH secretagogues (CJC-1295, ipamorelin, MK-677) for body composition and longevity benefits. Some consider combining them with GLP-1 medications for simultaneous muscle preservation and fat loss.

There is a pharmacological tension here: GLP-1 agonists lower blood glucose and enhance insulin sensitivity. GH secretagogues (particularly at higher doses or in insulin-resistant individuals) can increase glucose and worsen insulin sensitivity. These mechanisms conflict.

Is the combination dangerous? Not inherently—you are on opposite sides of the glucose spectrum, which might balance out in some individuals. Is it optimal? Probably not. You are, in some sense, fighting yourself pharmacologically.

If you are considering using both GLP-1 agonists and GH secretagogues, discuss this explicitly with your provider. Monitor glucose and lipids closely. Some people report that the GH secretagogue (which can increase appetite) partially counteracts the GLP-1’s appetite suppression. See our guide on why more is not always more for deeper context on peptide combinations.

The point of this discussion: if you are combining GLP-1s with other peptides, you should understand the pharmacological interactions. Do not assume they work synergistically—they may work at cross-purposes.

Frequently Asked Questions

The FAQ section is located in the accompanying FAQ text file (glp1-access-FAQ.txt) and is formatted for easy import into your content management system.

See the related resources below for additional depth on biomarkers, lab testing, provider evaluation, and regulatory status.